Keywords: Vanda Pharma, Tasimelteon, Non-24-hour disorder, Circadian regulator, Ph III
Vanda's tasimelteon meets primary endpoint in Ph III study
Article | 18 December 2012
Shares of USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) moved 2.8% higher to $3.22 in early trading yesterday, as the company announced positive results ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
